Yamashita Healthcare’s consolidated sales for the fiscal year ending May 2026 are \u00a564.1 billion (down 0.5% YoY), operating profit is \u00a5737 million, and net income is \u00a5648 million, both increasing. Forecasts for the next period include sales of \u00a569.7 billion, operating profit of \u00a5833 million, and net income of \u00a5553 million.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"9265","jir_company_name":"Yamashita Healthcare Holdings Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-07-13","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/07\/9265-20260713-01.pdf","jir_short_summary":"Yamashita Healthcare's consolidated sales for the fiscal year ending May 2026 are \u00a564.1 billion (down 0.5% YoY), operating profit is \u00a5737 million, and net income is \u00a5648 million, both increasing. Forecasts for the next period include sales of \u00a569.7 billion, operating profit of \u00a5833 million, and net income of \u00a5553 million.","jir_summary":"### Performance Overview\nYamashita Healthcare's fiscal year ending May 2026 recorded sales of \u00a564.1 billion (down 0.5% YoY), remaining nearly flat, but net income increased to \u00a5648 million (+5.1%), driven by strong medical device sales. The profit increase offset decreases in operating income due to rising personnel and system-related expenses, resulting in overall profit growth. Segment-wise, medical device sales are the main segment, supported by increases in testing and surgical procedures, as well as expansion of SPD contracts. Future projections include sales of \u00a569.7 billion, operating profit of \u00a5833 million, and net income of \u00a5553 million, with continued focus on medical DX and logistics efficiency improvements.\n\n### Outlook and Impact on Shareholders\nNext fiscal year expects sales to increase, though profits are projected to decrease due to rising personnel and logistics costs. Plans include sales of \u00a569.7 billion (+8.8%), operating profit of \u00a5833 million (+13.1%), and net income of \u00a5553 million (-14.6%). Dividends, including commemorative dividends, are planned at \u00a5107 per share (ordinary dividend \u00a577 + commemorative \u00a530), continuing shareholder returns. In the medium to long term, steady medical demand and DX promotion aim to enhance corporate value.","jir_financial_highlights":"Sales: \u00a564,149 million (YoY -0.5%)\nOperating profit: \u00a5737 million (YoY -12.1%)\nNet income attributable to owners of parent: \u00a5648 million (YoY +5.1%)","jir_category":"","jir_hashtags":"#YamashitaHealthcare, #IRFinancialResults, #JapaneseStocks","jir_key_figures":"Sales: \u00a564,149 million (down 0.5% YoY)\nNext period sales forecast: \u00a569.7 billion (+8.8%)\nNet income attributable to owners of parent: \u00a5648 million (+5.1%)","jir_meta_title":"\u3010Yamashita Healthcare\u3011Full-Year FY2026 Financial Results | Sales \u00a56.41 billion (YoY -0.5%)","jir_meta_description":"Yamashita Healthcare's FY2026 financial results show sales of \u00a564.1 billion and net income of \u00a5648 million, both increasing. Next period forecasts sales of \u00a569.7 billion with steady profit growth.","jir_og_title":"\u3010Yamashita Healthcare\u3011Full-Year FY2026 Financial Results | Sales \u00a56.41 billion (YoY -0.5%)","jir_og_description":"Yamashita Healthcare's FY2026 results are sales of \u00a564.1 billion, net income \u00a5648 million. Next period is projected to achieve sales of \u00a569.7 billion with profit expansion.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":0,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-80078","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n